Linzagolix

Generic Name
Linzagolix
Brand Names
Yselty
Drug Type
Small Molecule
Chemical Formula
C22H15F3N2O7S
CAS Number
935283-04-8
Unique Ingredient Identifier
7CDW97HUEX
Background

Linzagolix is a non-peptide, selective antagonist of the gonadotropin-releasing hormone (GnRH) receptor. It has been studied for the treatment of estrogen-dependent conditions such as uterine fibroids and endometriosis. It is similar to other GnRH receptor antagonists like cetrorelix, relugolix, and elagolix.

Uterine fibroids occur in >70% of women of reproductive age, and when symptomatic are associated with heavy menstrual bleeding, anemia, abdominal pain and pressure, bloating, increased urinary frequency, and reproductive dysfunction. As these fibroids are essentially estrogen-dependent phenomena, hormone therapies which suppress estrogen activity - including GnRH receptor antagonists like linzagolix - are thought to be beneficial by preventing intramyometrial growths in the endometrial glands.

Linzagolix was approved for use in the European Union in June 2022 for the management of symptoms caused by uterine fibroids.

Indication

Linzagolix is indicated for the treatment of moderate to severe symptoms of uterine fibroids in adult women of reproductive age.

Associated Conditions
Moderate Uterine Fibroids, Severe Uterine Fibroids
Associated Therapies
-
© Copyright 2024. All Rights Reserved by MedPath